참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Famciclovir | HCID 3324 | — |
| 반응물 | 2-Amino-6-chloropurine | HCID 5360349 | — |
| 반응물 | Triethyl 3-bromopropane-1,1,1-tricarboxylate | HCID 10871494 | — |
| 반응물 | Penciclovir | HCID 135398748 | — |
| 생성물 | Diethyl 2-[2-(2-amino-6-chloropurin-9-yl)ethyl]-2-carboxymalonate | HCID 22660291 | — |
반응 단계
Nucleosides and Nucleotides, 15(5), 981-994 (1996) and WO 95/28402 disclose a process for the manufacture of the anti-viral agents 9-(4-acetoxy-3-acetoxymethylbut-1-yl)-2-aminopurine (famciclovir) and 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (penciclovir). According to this process, the ‘bromoester’ route, 2-amino-6-chloropurine is reacted with triethyl 3-bromopropane-1,1,1-tricarboxylate in the presence of base to form diethyl 2-[2-(2-amino-6-chloropurin-9-yl)ethyl]-2-carboxymalonate. The crude isolate from this alkylation reaction is then treated with sodium methoxide in methanol to form dimethyl 2-[2-(2-amino-6-chloropurin-9-yl)ethyl]malonate. This product is purified by crystallisation and then successively reduced using sodium borohydride and O-acetylated to give 9-(4-acetoxy-3-acetoxymethylbutyl)-2-amino-6-chloropurine. Famciclovir is produced directly from the latter compound by hydrogenation over a supported palladium catalyst; and penciclovir is produced from this compound by acid hydrolysis of the acetoxy groups.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US06806375B2 |
|---|
| 출처 데이터셋 | uspto-grants-2004_10 |
|---|
| ORD ID | ord-dda2fc820c3d46468a6fe2c3ee583d55 |
|---|
| 출처 메모 | uspto-grants-2004_10 |
|---|